Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 24:12:109.
doi: 10.1186/1477-7827-12-109.

Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta-analysis

Yujing Xiong, Zhiqin Bu, Wei Dai, Meixiang Zhang, Xiao Bao, Yingpu Sun  1
Affiliations

Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta-analysis

Yujing Xiong et al. Reprod Biol Endocrinol. .

Abstract

The objective of this meta-analysis is to assess the impact of LH supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection (IVF/ICSI) with gonadotropin releasing hormone (GnRH) antagonist protocol. No significant difference in outcomes between LH supplementation and r-FSH alone in women undergoing IVF/ICSI with GnRH antagonist protocol is currently present, and further studies are necessary for more solid conclusions on pregnancy likelihood to be drawn.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the study selection process used for a systematic review and meta-analysis, undertaken to investigate the effect of recombinant human luteinizing hormone supplementation in women undergoing IVF/ICSI with antagonist protocol.
Figure 2
Figure 2
Forest plot of ongoing pregnancy per ET with or without r-LH supplementation for COH in general population undergoing IVF or ICSI-ET with GnRH antagonist protocol.
Figure 3
Figure 3
Forest plot of clinical pregnancy per ET with or without r-LH supplementation for COH in general population undergoing IVF or ICSI-ET with GnRH antagonist protocol.
Figure 4
Figure 4
Forest plot of incidence of OHSS with or without r-LH supplementation for COH in general population undergoing IVF or ICSI-ET with GnRH antagonist protocol.
Figure 5
Figure 5
Forest plot of serum oestrodial level on hCG day with or without r-LH supplementation for COH in general population undergoing IVF or ICSI-ET with GnRH antagonist protocol.
Figure 6
Figure 6
Forest plot of serum progesterone level on hCG day with or without r-LH supplementation for COH in general population undergoing IVF or ICSI-ET with GnRH antagonist protocol.
Figure 7
Figure 7
Forest plot of rFSH total dose used per treatment cycle with or without r-LH supplementation for COH in advanced reproductive aged women undergoing IVF or ICSI-ET with GnRH antagonist protocol.
Figure 8
Figure 8
Forest plot of serum oestrodial level on hCG day with or without r-LH supplementation for COH in advanced reproductive aged women undergoing IVF or ICSI-ET with GnRH antagonist protocol.
Figure 9
Figure 9
Forest plot of number of retrieved oocytes per oocyte retrieval with or without r-LH supplementation for COH in advanced reproductive aged women undergoing IVF or ICSI-ET with GnRH antagonist protocol.
Figure 10
Figure 10
Forest plot of total days of stimulation per treatment cycle with or without r-LH supplementation for COH in women undergoing IVF or ICSI-ET with GnRH antagonist protocol and oral contraceptive pills pretreatment.
Figure 11
Figure 11
Forest plot of serum progesterone level on hCG day with or without r-LH supplementation for COH in women undergoing IVF or ICSI-ET with GnRH antagonist protocol and oral contraceptive pills pretreatment.
See this image and copyright information in PMC

References

    1. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 1997;67:917–922. doi: 10.1016/S0015-0282(97)81407-0. - DOI - PubMed
    1. Lindheim SR, Morales AJ. GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod. 2003;18:2048–2051. doi: 10.1093/humrep/deg407. - DOI - PubMed
    1. Mochtar MH, der Veen V, Ziech M, van Wely M. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2007;2:CD005070. - PubMed
    1. Ferraretti AP, Gianaroli L, Magli MC, D'Angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril. 2004;82:1521–1526. doi: 10.1016/j.fertnstert.2004.06.041. - DOI - PubMed
    1. Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, Hornung D, Diedrich K, Felberbaum R. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod. 2005;20:1200–1206. doi: 10.1093/humrep/deh741. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources